Neuroendocrine Tumor Treatment Market
SummaryNETs can infect a range of glands such as thymus, thyroid, adrenal and pituitary gland. Efficient treatment for neuroendocrine tumor is extremely necessary because if the tumor is malignant in nature; it might spread to nearby tissues or lymph nodes, eventually spreading throughout the body.
Neuroendocrine tumors (NETs) emerge from hormone-producing cells of body’s neuroendocrine system and nervous system. NETs tend to release higher-than-normal amounts of hormones and impact negatively the important body organs such as the lungs, gastrointestinal tract, stomach and intestines and various body functions. These tumors may be benign or malignant in nature. Some examples of neuroendocrine tumors are carcinoid tumors, islet cell tumors, medullary thyroid cancer, pheochromocytomas, neuroendocrine carcinoma of the skin (Merkel cell cancer), small cell lung cancer, and large cell neuroendocrine carcinoma (a rare type of lung cancer). The tumors begins with infecting the intestine and form carcinoid tumors, followed by pancreas.
NETs can infect a range of glands such as thymus, thyroid, adrenal and pituitary gland. Efficient treatment for neuroendocrine tumor is extremely necessary because if the tumor is malignant in nature; it might spread to nearby tissues or lymph nodes, eventually spreading throughout the body. The treatment options for NETs are limited in number and include surgical removal of tumors, chemotherapy, targeted therapy and radiation therapy, etc. There is no standard treatment for treating neuroendocrine tumor but two novel targeted therapy drugs- Afinitor and Sutent have been approved by FDA for treatment of advanced pancreatic neuroendocrine tumors and is beneficial for some patients according to the type and severity of the indication.
Globally, increasing incidences of NET among patients mainly due to disorders such as Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL) and Tuberous sclerosis complex (TSC) disease. However, in October, 2017, JAMA Oncology Journal published an article stating that the survival rate for all Neuroendocrine Tumor Treatment Market has improved, especially for distant-stage gastrointestinal Neuroendocrine Tumor Treatment Market and pancreatic Neuroendocrine Tumor Treatment Market. This is attributed to availability of better therapies and early detection and diagnosis techniques. Thus, introduction of new therapies and extended indications for approved drugs is expected to augment NET treatment industry. Targeted therapy is one of the most preferred methods to treat neuroendocrine tumor. Such innovative and highly effective approach for treating cancers is also responsible for gaining traction during the forecast period.
Request For Sample Of The Report @ <p><a href="https://www.researchreport.co.uk/Request-Sample/100097">https://www.researchreport.co.uk/Request-Sample/100097</a></p>
Increasing adoption of advanced diagnostic imaging techniques such as endoscopic ultrasonography etc. would result in discovery of NETs which are small in size and are relatively clinically insignificant. These kind of tumors are not related to the symptoms and may not require surgical excision and hence, requiring other techniques for treating the tumor, resulting in fueling the market.
The neuroendocrine treatment market is segmented on the basis of drug, indication, end user and geography. Based on drug, the NET market is categorized into Everolimus, Sunitinib Malate, Lu-Dotate, Lanreotide, and Octreotide. On the basis of indication, the segment is bifurcated into gastrointestinal neuroendocrine tumor, lung neuroendocrine tumor, pancreatic neuroendocrine tumor and others neuroendocrine Tumor. Whereas, hospitals, oncology centers, and others including GI centers, cardio-thoracic centers, NET centers are few end users in this industry. Geographically, the NET treatment market is bifurcated into North America, Europe, Asia Pacific, Middle East &Africa and Latin America.
The North America region is expected to dominate the neuroendocrine tumor treatment market during the forecast period owing to the establishment of various national universities and small scale pharmaceutical companies researching and developing effective drug for NET, capable of modifying clinical approach to treat neuroendocrine tumors. Thus, pharmaceutical and biotechnology companies have a major opportunity to progress in the U.S. NET treatment industry.
Some of the key players of NET treatment market are Advanced Accelerator Applications, Novartis AG, Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., Ispen, Tarveda Therapeutics, Exelixis, Inc., Pfizer Inc, and Progenics Pharmaceuticals, Inc.
Get more Information about this Report @ <p><a href="https://www.researchreport.co.uk/Reports/Neuroendocrine-Tumor-Treatment-Market">https://www.researchreport.co.uk/Reports/Neuroendocrine-Tumor-Treatment-Market</a></p>